Over 12 months, Bolt Biotherapeutics, Inc. saw more selling than buying from its insiders — purchases of about $6,971 against sales of $128,000.
Quinn William P. (CEO) made the biggest buy, worth around $2,472. C-suite participation is part of the picture here.
23 investment managers listed BOLT in their latest 13F filings (Q2 2026); funds were split between buying and selling. Quarter by quarter: Last full quarter: net selling by insiders. Insiders bought in 3 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Yonehiro Grant | COO | Sell | 4,909 | $3.32 | $16K | SEC |
| Sep 21, 2026 | Yonehiro Grant | COO | Sell | 6,850 | $3.24 | $22K | SEC |
| Sep 21, 2026 | Yonehiro Grant | COO | Sell | 1,417 | $3.77 | $5K | SEC |
| Sep 21, 2026 | Nemec Sarah | Officer | Sell | 2,922 | $3.32 | $10K | SEC |
| Sep 21, 2026 | Nemec Sarah | Officer | Sell | 4,077 | $3.24 | $13K | SEC |
| Sep 21, 2026 | Nemec Sarah | Officer | Buy | 509 | $3.88 | $2K | SEC |
| Sep 21, 2026 | Nemec Sarah | Officer | Sell | 843 | $3.77 | $3K | SEC |
| Sep 21, 2026 | Quinn William P. | CEO | Sell | 1,889 | $3.77 | $7K | SEC |
| Sep 21, 2026 | Quinn William P. | CEO | Buy | 637 | $3.88 | $2K | SEC |
| Sep 21, 2026 | Quinn William P. | CEO | Sell | 6,545 | $3.32 | $22K | SEC |
| Sep 21, 2026 | Quinn William P. | CEO | Sell | 9,132 | $3.24 | $30K | SEC |
| Feb 4, 2026 | Quinn William P. | CEO | Buy | 125 | $4.61 | $576 | SEC |
| Feb 4, 2026 | Nemec Sarah | Officer | Buy | 125 | $4.61 | $576 | SEC |
| Oct 24, 2025 | Nemec Sarah | Officer | Buy | 125 | $5.49 | $686 | SEC |
| Oct 24, 2025 | Quinn William P. | CEO | Buy | 125 | $5.49 | $686 | SEC |
In the last 12 months Bolt Biotherapeutics, Inc. insiders made open-market purchases worth about $6,971 and sales worth about $128,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in BOLT was filed on 2026-09-21.
23 investment managers reported holding BOLT in SEC Form 13F filings for Q2 2026.
No congressional trades in BOLT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).